Immunocore Holdings plc (NASDAQ:IMCR) Receives Average Rating of “Moderate Buy” from Brokerages

Immunocore Holdings plc (NASDAQ:IMCR) has received an average rating of “Moderate Buy” from the thirteen brokerages that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $65.64.

Several equities analysts have commented on the stock. Morgan Stanley reiterated an “equal weight” rating and set a $35.00 price objective (down previously from $74.00) on shares of Immunocore in a research report on Friday, December 13th. HC Wainwright reiterated a “buy” rating and set a $100.00 price objective on shares of Immunocore in a research report on Monday, January 27th. Needham & Company LLC reiterated a “buy” rating and set a $71.00 price objective on shares of Immunocore in a research report on Friday, January 10th. Finally, Mizuho lowered shares of Immunocore from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $72.00 to $38.00 in a research report on Monday, November 11th.

Institutional Investors Weigh In On Immunocore

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IMCR. GF Fund Management CO. LTD. bought a new stake in Immunocore during the 4th quarter valued at about $25,000. China Universal Asset Management Co. Ltd. lifted its holdings in Immunocore by 69.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock valued at $231,000 after buying an additional 3,053 shares in the last quarter. NEOS Investment Management LLC lifted its holdings in Immunocore by 10.9% during the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock valued at $330,000 after buying an additional 1,102 shares in the last quarter. Tema Etfs LLC bought a new stake in Immunocore during the 4th quarter valued at about $330,000. Finally, Virtus ETF Advisers LLC lifted its holdings in Immunocore by 39.0% during the 4th quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company’s stock valued at $340,000 after buying an additional 3,238 shares in the last quarter. Institutional investors own 84.50% of the company’s stock.

Immunocore Price Performance

IMCR stock opened at $29.92 on Monday. Immunocore has a 52 week low of $27.69 and a 52 week high of $72.56. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The company has a fifty day simple moving average of $29.97 and a two-hundred day simple moving average of $32.08. The firm has a market capitalization of $1.50 billion, a P/E ratio of -31.49 and a beta of 0.77.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.